Efficacy: High-Risk Non-muscle Invasive Bladder Cancer
Safety Profile: High-Risk Non-muscle Invasive Bladder Cancer
Efficacy: Advanced MSI-H/dMMR Cancers
Safety Profile: Advanced MSI-H/dMMR Cancers
Efficacy: Advanced Gastric or GEJ Cancer
Safety Profile: Advanced Gastric or GEJ Cancer
Efficacy: Advanced MSI-H/dMMR CRC
Safety Profile: Advanced MSI-H/dMMR CRC
Efficacy: Advanced Esophageal or GEJ Carcinoma
Safety Profile: Advanced Esophageal or GEJ Carcinoma
Efficacy: First-line Combination Therapy for Advanced Cervical Cancer
Safety Profile: First-line Combination Therapy for Advanced Cervical Cancer
Efficacy: Second-line Monotherapy for Advanced Cervical Cancer
Safety Profile: Second-line Monotherapy for Advanced Cervical Cancer
Efficacy: Advanced Merkel Cell Carcinoma
Safety Profile: Advanced Merkel Cell Carcinoma
Efficacy: Adjuvant Treatment for Renal Cell Carcinoma
Safety Profile: Adjuvant Treatment for Renal Cell Carcinoma
Efficacy: Advanced Renal Cell Carcinoma
Safety Profile: Advanced Renal Cell Carcinoma
drug label
Keytruda prescribing information
Have more Keytruda questions?
Submit MSL Request
Learn More
Your request will be referred to the appropriate Merck Sharp & Dohme LLC medical professional, such as a Keytruda pharmaceutical rep; Medical Science Liaison (MSL) or medical affairs.
Need to report a Keytruda issue?
ONLINE FORMReport adverse event
Learn More
You can report a Keytruda adverse event on MedWatch, the FDA's medical product safety reporting program for health professionals, patients and consumers.
prior authorization
Keytruda Prior authorization resources
NOT PROVIDED BY BRANDComplete Letter of Medical Necessity
Coverage Authorization Request
Coverage Authorization Appeals
Learn More
If available, these templates are provided by the brand to help you navigate insurance, especially with newer drugs.
Benefits investigation
2022 Merck Access Program Enrollment Form
2023 Merck Access Program Enrollment Form
Merck Access Program - 2023 Healthcare Provider Enrollment Form
2022 Merck Access Program Electronic Enrollment Form
2023 Merck Access Program Electronic Enrollment Form
Merck Access Program - 2023 Healthcare Provider Electronic Enrollment Form
Learn More
Benefits investigations are conducted to determine whether a therapy is covered under a patient's insurance, if a prior authorization is required, and which specialty pharmacies are preferred.
Reimbursement help (FRM)
Receive Assistance from an FRM Regarding Reimbursement Information
Learn More
Some brands offer a field reimbursement manager who will work with your clinical staff and preferred pharmacy to help make sure patients don't fall through the cracks.
financial assistance
Keytruda Financial assistance options
Co-pay savings program
commercial only
2022 Merck Access Program Enrollment Form
2023 Merck Access Program Enrollment Form
Merck Access Program - 2023 Healthcare Provider Enrollment Form
2022 Merck Access Program Electronic Enrollment Form
2023 Merck Access Program Electronic Enrollment Form
Merck Access Program - 2023 Healthcare Provider Electronic Enrollment Form
Enroll in Patient Savings Program
Learn More
Overview
Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance
How to sign up
Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Bridge program
commercial only
Learn More
Overview
Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)
Patient benefit
100% free (outside of insurance)
Patient eligibility
HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries
How to sign up
Typically HCP assisted enrollment (via form)
Foundation programs
under insured
no insurance
goverment insurance
65+
2022 Merck Access Program Enrollment Form
2023 Merck Access Program Enrollment Form
Merck Access Program - 2023 Healthcare Provider Enrollment Form
2022 Merck Access Program Electronic Enrollment Form
2023 Merck Access Program Electronic Enrollment Form
Merck Access Program - 2023 Healthcare Provider Electronic Enrollment Form
Merck Patient Assistance Program Application
Learn More
Overview
Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned
Patient benefit
Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted
Patient eligibility
Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.
How to sign up
Patients submit proof of out-of-pocket drug costs to charities for reimbursement
patient education
Keytruda Patient education
Getting started on Keytruda
NOT PROVIDED BY BRANDInstructions For Use: Advanced Melanoma
NOT PROVIDED BY BRANDInstructions For Use: Adjuvant Therapy for Stage IIB, Stage IIC, or Stage III Melanoma
NOT PROVIDED BY BRANDInstructions For Use: First-line Combination Therapy in Nonsquamous mNSCLC
NOT PROVIDED BY BRANDInstructions For Use: First-line Combination Therapy in Squamous mNSCLC
NOT PROVIDED BY BRANDInstructions For Use: First-line Monotherapy for Nonsquamous and Squamous Advanced NSCLC
NOT PROVIDED BY BRANDInstructions For Use: Second-line or Greater Monotherapy for Nonsquamous and Squamous mNSCLC
NOT PROVIDED BY BRANDInstructions For Use: Subsequent-line Monotherapy in Recurrent or Metastatic HNSCC
NOT PROVIDED BY BRANDInstructions For Use: First-line Combination Therapy in Metastatic or Unresectable, Recurrent HNSCC
NOT PROVIDED BY BRANDInstructions For Use: First-line Monotherapy in Metastatic or Unresectable, Recurrent HNSCC
NOT PROVIDED BY BRANDInstructions For Use: Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
NOT PROVIDED BY BRANDInstructions For Use: Refractory or Relapsed PMBCL
NOT PROVIDED BY BRANDInstructions For Use: First-line Monotherapy for Advanced Urothelial Carcinoma
NOT PROVIDED BY BRANDInstructions For Use: Second-line Monotherapy—Post–Platinum Failure
NOT PROVIDED BY BRANDInstructions For Use: High-Risk Non-muscle Invasive Bladder Cancer
NOT PROVIDED BY BRANDInstructions For Use: Advanced MSI-H/dMMR Cancers
NOT PROVIDED BY BRANDInstructions For Use: Advanced Gastric or GEJ Cancer
NOT PROVIDED BY BRANDInstructions For Use: Advanced MSI-H/dMMR CRC
NOT PROVIDED BY BRANDInstructions For Use: Advanced Esophageal or GEJ Carcinoma
NOT PROVIDED BY BRANDInstructions For Use: First-line Combination Therapy for Advanced Cervical Cancer
NOT PROVIDED BY BRANDInstructions For Use: Second-line Monotherapy for Advanced Cervical Cancer
NOT PROVIDED BY BRANDInstructions For Use: Advanced Hepatocellular Carcinoma
NOT PROVIDED BY BRANDInstructions For Use: Advanced Merkel Cell Carcinoma
NOT PROVIDED BY BRANDInstructions For Use: Adjuvant Treatment for Renal Cell Carcinoma
Patient toolkit
NOT PROVIDED BY BRANDNot Provided By Brand
Learn More
Other resources brands publish to help support patients and caregivers.
people also ask
Keytruda FAQs
FAQ Data Source
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available
Can't find what you're looking for?
Our trained staff can help you:
Please note:
Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
Samples are provided at the discretion of the brand.
We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.